Literature DB >> 9869319

Alzheimer-type lesions in Huntington's disease.

K A Jellinger1.   

Abstract

Cognitive changes in Huntington's disease (HD) are variously related to diffuse cortical atrophy with neuron loss and dystrophic neurites leading to disruption of striato-frontal or limbic circuitries, while recent studies suggest an increasing prevalence of Alzheimer-like lesions in HD brain. A comparative morphological study of 27 autopsy cases of HD (age 34 to 75 years) and of 26 age- and sex-matched non-demented controls was performed. Absence of Alzheimer-type lesions was seen in 33% of HD brains (mean age 49 years); 48% showed early non-neuritic tau pathology in limbic areas (Braak stages I and II) without amyloid deposits occurring as early as age 34 years (mean age 54 years), while Braak stages II and III with amyloid plaques were present in 19%, the youngest such HD patient being 42 years (mean age 54 years). In controls, similar tau pathology changes with later onset (age 45 years) and occurrence of amyloid plaques in 26%--all aged over 60 years--were observed. No probable or definite cases of Alzheimer disease (AD) according to CERAD criteria were seen in both cohorts. Those data confirm previous studies on the rare coexistence of HD and AD, although initial stages of Alzheimer-like lesions develop rather early in HD patients, but obviously show less rapid progress even in advanced age. The reasons for the early onset but mild progress of Alzheimer-like lesions in HD and their contribution to cognitive decline await further elucidation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869319     DOI: 10.1007/s007020050095

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  17 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Selective reduction of amyloid beta42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation.

Authors:  B Mollenhauer; M Bibl; H Esselmann; P Steinacker; C Trenkwalder; P Brechlin; J Wiltfang; M Otto
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

3.  Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease.

Authors:  Giulia Cisbani; Alexander Maxan; Jeffrey H Kordower; Emmanuel Planel; Thomas B Freeman; Francesca Cicchetti
Journal:  Brain       Date:  2017-11-01       Impact factor: 13.501

4.  Classification of diseases with accumulation of Tau protein.

Authors:  Gabor G Kovacs; Bernardino Ghetti; Michel Goedert
Journal:  Neuropathol Appl Neurobiol       Date:  2022-02-09       Impact factor: 6.250

5.  Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.

Authors:  Melanie Alpaugh; Maria Masnata; Aurelie de Rus Jacquet; Eva Lepinay; Hélèna L Denis; Martine Saint-Pierre; Peter Davies; Emmanuel Planel; Francesca Cicchetti
Journal:  Mol Ther       Date:  2022-01-17       Impact factor: 12.910

6.  The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome.

Authors:  Yvonne S Davidson; Andrew Robinson; Vee P Prasher; David M A Mann
Journal:  Acta Neuropathol Commun       Date:  2018-07-04       Impact factor: 7.801

7.  Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer's disease.

Authors:  Maike Hartlage-Rübsamen; Veronika Ratz; Ulrike Zeitschel; Lukas Finzel; Lisa Machner; Janett Köppen; Anja Schulze; Hans-Ulrich Demuth; Stephan von Hörsten; Corinna Höfling; Steffen Roßner
Journal:  Acta Neuropathol Commun       Date:  2019-05-20       Impact factor: 7.801

8.  The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau).

Authors:  Yin Xu; Sheng Zhang; Hui Zheng
Journal:  Autophagy       Date:  2018-10-16       Impact factor: 13.391

9.  The role of tau in the pathological process and clinical expression of Huntington's disease.

Authors:  Romina Vuono; Sophie Winder-Rhodes; Rohan de Silva; Giulia Cisbani; Janelle Drouin-Ouellet; Maria G Spillantini; Francesca Cicchetti; Roger A Barker
Journal:  Brain       Date:  2015-05-06       Impact factor: 13.501

Review 10.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.